Triple‐negative breast cancer: Present challenges and new perspectives

Podo, Franca; Buydens, Lutgarde M.C.; Degani, Hadassa; Hilhorst, Riet; Klipp, Edda; Gribbestad, Ingrid S.; Van Huffel, Sabine; W.M. van Laarhoven, Hanneke; Luts, Jan; Monleon, Daniel; Postma, Geert J.; Schneiderhan-Marra, Nicole; Santoro, Filippo; Wouters, Hans; Russnes, Hege G.; Sørlie, Therese; Tagliabue, Elda; Børresen-Dale, Anne-Lise

doi:10.1016/j.molonc.2010.04.006

Cited by 299Breast Cancer Treatment StudiesBreast Lesions and CarcinomasBRCA gene mutations in cancer

Triple‐negative breast cancer: Present challenges and new perspectives

Open access

Podo, Franca, Buydens, Lutgarde M.C., Degani, Hadassa, Hilhorst, Riet, Klipp, Edda, Gribbestad, Ingrid S., Van Huffel, Sabine, W.M. van Laarhoven, Hanneke +10 more·2010·Molecular Oncology

DOI 10.1016/j.molonc.2010.04.006PMC PMC5527939

Open this paper in CoChat — free account Open PDF

Abstract

Triple‐negative breast cancers (TNBC), characterized by absence of estrogen receptor (ER), progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), are typically associated with poor prognosis, due to aggressive tumor phenotype(s), only partial response to chemotherapy and present lack of clinically established targeted therapies. Advances in the design of individualized strategies for treatment of TNBC patients require further elucidation, by combined ‘omics’ approaches, of the molecular mechanisms underlying TNBC phenotypic heterogeneity, and the still poorly understood association of TNBC with BRCA1 mutations. An overview is here presented on TNBC profiling in terms of expression signatures, within the functional genomic breast tumor classification, and ongoing efforts toward identification of new therapy targets and bioimaging markers. Due to the complexity of aberrant molecular patterns involved in expression, pathological progression and biological/clinical heterogeneity, the search for novel TNBC biomarkers and therapy targets requires collection of multi‐dimensional data sets, use of robust multivariate data analysis techniques and development of innovative systems biology approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2010.04.006

Cites

213 of 213 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks effective treatment.
“Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks effective treatment1,2.”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [2]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer
Acharya, C. R., Hsu, D. S., Anders, C. K., Anguiano, A., Salter, K. H., Walters, K. S., Redman, R. C., Tuchman, S. A., Moylan, C. A., Mukherjee, S., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1574 · Cited by 108 · see citing works
Retracted
The Nature of Statistical Learning Theory
Vapnik, V. N. (1995) · doi:10.1007/978-1-4757-2440-0 · Cited by 39,138 · see citing works
Pattern Classification
Seel, N. M. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1428-6_5195 · Cited by 19,525 · see citing works
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551 · see citing works
Self-citation
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., Veer, L. V. ‘., Dai, H. A., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,411 · see citing works
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · see citing works
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069 · see citing works
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,428 · see citing works
Self-citation
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · see citing works
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,737 · see citing works
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382 · see citing works
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L., Perou, C. M., Livasy, C., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S. N., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,810 · see citing works
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645 · see citing works
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works
The human disease network
Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242 · see citing works
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,191 · see citing works
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892 · see citing works
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Nielsen, T. O., Hsu, F. D., Jensen, K. C., Cheang, M. C. U., Karaca, G., Hu, Z., Hernandez‐Boussard, T., Livasy, C., Cowan, D., Dressler, L. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,665 · see citing works
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544 · see citing works
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F. A., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,086 · see citing works
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype
Bauer, K. R., Brown, M. M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,069 · see citing works
The epithelial–mesenchymal transition: new insights in signaling, development, and disease
Lee, J. M., Dedhar, S., Kalluri, R., & Thompson, E. W. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200601018 · Cited by 2,011 · see citing works
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. K., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J. J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,889 · see citing works
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850 · cited 2× · see citing works
“…progression and outcome (Breast Cancer Linkage Consortium, 1997; Lakhani et al., 1998, 2002; Verhoog et al., 1998; Moller et al., 2002; Narod and Foulkes, 2004; Robson et al., 2004; Brekelmans et al., 2006; Bonadona et al., 2007; Moller et al., 2007; Honrado et al., 2007; Melchor and Benitez,…”
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713 · see citing works
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed · Cited by 1,580 · see citing works
The molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J. S., He, X., Qaqish, B. F., Livasy, C., Carey, L., Reynolds, E. R., Dressler, L. G., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,492 · see citing works
Network‐based classification of breast cancer metastasis
Chuang, H., Lee, E., Liu, Y., Lee, D., & Ideker, T. (2007) · Molecular Systems Biology · doi:10.1038/msb4100180 · Cited by 1,431 · see citing works
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402 · see citing works
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B. J. K., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,369 · see citing works
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311 · see citing works
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,288 · see citing works
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F. R., & Ellis, I. O. (2006) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,284 · see citing works
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2713 · Cited by 1,254 · see citing works
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Cheang, M. C. U., Voduc, D. K., Bajdik, C. D., Leung, S. C. Y., McKinney, S. E., Chia, S., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,197 · see citing works
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164 · see citing works
Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
Haffty, B. G., Yang, Q., Reiß, M., Kearney, T. J., Higgins, S. A., Weidhaas, J. B., Harris, L. N., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,085 · see citing works
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C., Karaca, G., Nanda, R., Tretiakova, M., Olopade, O. I., Moore, D. T., & Perou, C. M. (2005) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,064 · see citing works
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
Chang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., Dai, H., He, Y. D., van't Veer, L. J., Bartelink, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409462102 · Cited by 981 · see citing works
Self-citation
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg050 · Cited by 970 · see citing works
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967 · see citing works
p53 and metabolism
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · see citing works
Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors
Schoeberl, B., Eichler-Jonsson, C., Gilles, E. D., & Müller, G. I. (2002) · Nature Biotechnology · doi:10.1038/nbt0402-370 · Cited by 952 · see citing works
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Lakhani, S., van de Vijver, M., Jacquemier, J., Anderson, T., Osin, P., McGuffog, L., & Easton, D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 888 · see citing works
Triple-negative breast cancer: therapeutic options
Cleator, S. J., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 884 · see citing works
Triple negative tumours: a critical review
Reis-Filho, J. S., & Tutt, A. N. J. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 883 · see citing works
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis
Shen, R., Olshen, A. B., & Ladanyi, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp543 · Cited by 849 · see citing works
Complex landscapes of somatic rearrangement in human breast cancer genomes
Stephens, P. J., McBride, D. J., Lin, M., Varela, I., Pleasance, E., Simpson, J. T., Stebbings, L. A., Leroy, C., Edkins, S., Mudie, L. J., et al. (2009) · Nature · doi:10.1038/nature08645 · Cited by 833 · see citing works
Self-citation
Subtypes of Breast Cancer Show Preferential Site of Relapse
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J. X., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5644 · Cited by 817 · see citing works
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R. A., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798 · see citing works
System-level identification of transcriptional circuits underlying mammalian circadian clocks
Ueda, H. R., Hayashi, S., Chen, W., Sano, M., Machida, M., Shigeyoshi, Y., Iino, M., & Hashimoto, S. (2005) · Nature Genetics · doi:10.1038/ng1504 · Cited by 786 · see citing works
The role of epithelial-mesenchymal transition in cancer pathology
Guarino, M., Rubino, B., & Ballabio, G. (2007) · Pathology · doi:10.1080/00313020701329914 · Cited by 782 · see citing works
The Roles of APC and Axin Derived from Experimental and Theoretical Analysis of the Wnt Pathway
Lee, E., Salic, A., Krüger, R., Heinrich, R., & Kirschner, M. W. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000010 · Cited by 708 · see citing works
Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707 · see citing works
Breast cancer: origins and evolution
Polyák, K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33295 · Cited by 703 · see citing works
Circadian Rhythms: Mechanisms and Therapeutic Implications
Levi, F., & Schibler, U. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105208 · Cited by 645 · see citing works
Negative feedback and ultrasensitivity can bring about oscillations in the mitogen‐activated protein kinase cascades
Kholodenko, B. N. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01197.x · Cited by 643 · see citing works
Integrative Analysis of Cell Cycle Control in Budding Yeast
Chen, K. C., Calzone, L., Csikász‐Nagy, A., Cross, F. R., Novák, B., & Tyson, J. J. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0794 · Cited by 625 · see citing works
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
Kreike, B., van Kouwenhove, M., Horlings, H. M., Weigelt, B., Peterse, H. L., Bartelink, H. G. M. M., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613 · see citing works
Network modeling links breast cancer susceptibility and centrosome dysfunction
Pujana, M. Á., Han, J.-D. J., Starita, L. M., Purrington, K. S., Tewari, M., Ahn, J. S., Rennert, G., Moreno, V. R., Kirchhoff, T., Gold, B., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.2 · Cited by 611 · see citing works
Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients
Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P. A., Schwartz, G. F., Park, P. K., Rosenberg, A., Brill, K. L., et al. (2007) · Cancer · doi:10.1002/cncr.22836 · Cited by 603 · see citing works
Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility
Giampieri, S., Manning, C. S., Hooper, S., Jones, J. L., Hill, C. S., & Sahai, E. A. (2009) · Nature Cell Biology · doi:10.1038/ncb1973 · Cited by 602 · see citing works
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579 · see citing works
Systems biology and combination therapy in the quest for clinical efficacy
Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570 · see citing works
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis
Shen, R., Olshen, A. B., & Ladanyi, M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp659 · Cited by 566 · see citing works
Refinement of breast cancer classification by molecular characterization of histological special types
Weigelt, B., Horlings, H. M., Kreike, B., Hayes, M., Hauptmann, M., Wessels, L. F. A., de Jong, D., van de Vijver, M. J., Veer, L. V., & Peterse, J. L. (2008) · The Journal of Pathology · doi:10.1002/path.2407 · Cited by 560 · see citing works
Inferring tumor progression from genomic heterogeneityPreprint
Navin, N. E., Krasnitz, A., Rodgers, L., Cook, K., Meth, J. L., Kendall, J., Riggs, M. G., Eberling, Y., Troge, J. E., Grubor, V. D., et al. (2009) · Genome Research · doi:10.1101/gr.099622.109 · Cited by 515 · see citing works
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer
Bergamaschi, A., Kim, Y. H., Wang, P., Sørlie, T., Hernandez‐Boussard, T., Lønning, P. E., Tibshirani, R. J., Børresen‐Dale, A., & Pollack, J. R. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20366 · Cited by 506 · see citing works
Self-citation
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El‐Sayed, M. E., Benhasouna, A., Brunet, J., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 490 · see citing works
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Thomas, E. S., Gómez, H., Li, R. K., Chung, H. C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J., Mendoza, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 489 · see citing works
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Burstein, H. J., ELIAS, A. D., Rugo, H. S., Cobleigh, M., Wolff, A. C., Eisenberg, P. D., Lehman, M. J., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489 · see citing works
Logistic Regression Model to Distinguish Between the Benign and Malignant Adnexal Mass Before Surgery: A Multicenter Study by the International Ovarian Tumor Analysis Group
Timmerman, D., Testa, A. C., Bourne, T., Ferrazzi, E. M., Ameye, L., Konstantinovic, M. L., CALSTER, B. V., Collins, W. P., Vergote, I. B., Huffel, S. V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7632 · Cited by 480 · see citing works
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Kassam, F., Enright, K. A., Dent, R. A., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R. D., & Clemons, M. J. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474 · see citing works
Kinetic Analysis of a Molecular Model of the Budding Yeast Cell Cycle
Chen, K. C., Csikász‐Nagy, A., Györffy, B., Val, J., Novák, B., & Tyson, J. J. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.1.369 · Cited by 466 · see citing works
BRCA1 regulates human mammary stem/progenitor cell fate
Liu, S., Ginestier, C., Charafe‐Jauffret, E., Foco, H., Kleer, C. G., Merajver, S. D., Dontu, G., & Wicha, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711613105 · Cited by 461 · see citing works
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452 · see citing works
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438 · see citing works
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J. E., Perou, C. M., Richardson, A. L., Sledge, G. W., & Carey, L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437 · see citing works
HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Marín‐Hernández, Á., Gallardo‐Pérez, J. C., Ralph, S. J., Rodríguez‐Enríquez, S., & Moreno‐Sánchez, R. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709788922610 · Cited by 433 · see citing works
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 429 · see citing works
Evidence for a stem cell hierarchy in the adult human breast
Villadsen, R., Fridriksdottir, A. J., Rønnov‐Jessen, L., Guðjónsson, Þ., Rank, F. E., LaBarge, M. A., Bissell, M. J., & PETERSEN, O. W. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611114 · Cited by 418 · see citing works
Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data
Chen, W. W., Schoeberl, B., Jasper, P. J., Niepel, M., Nielsen, U. B., Lauffenburger, D. A., & Sorger, P. K. (2009) · Molecular Systems Biology · doi:10.1038/msb.2008.74 · Cited by 391 · see citing works
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B. R., Brawley, O. W., Flagg, E. W., O’Regan, R. M., Gabram, S. G. A., & Eley, J. W. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9926-3 · Cited by 390 · see citing works
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B. E., Kalra, A. V., Paragas, V. B., Bukhalid, R. A., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 358 · see citing works
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
Fulford, L. G., Easton, D. F., Reis-Filho, J. S., Sofronis, A., Gillett, C., Lakhani, S. R., & Hanby, A. M. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02453.x · Cited by 351 · see citing works
What is triple-negative breast cancer?
Irvin, W., & Carey, L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 350 · see citing works
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J. P., CLYNES, M. M., & O’Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348 · see citing works
Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
Uematsu, T., Kasami, M., & Yuen, S. (2009) · Radiology · doi:10.1148/radiol.2503081054 · Cited by 347 · see citing works
Tumour biological features of BRCA1-induced breast and ovarian cancer
Johannsson, O. T., Idvall, I., Anderson, C., Borg, Å., Barkardottir, R. B., Egilsson, V., & Olsson, H. L. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 344 · see citing works
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R. A., Gronwald, J., Zuziak, D., Cybulski, C., Kładny, J., Górski, B., Lubiński, J., & Narod, S. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 339 · see citing works
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332 · see citing works
Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas
Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J. J., & Palacios, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2281 · Cited by 324 · see citing works
Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B., Overgaard, J., Nielsen, K. V., Schönau, A., Gunnarsdóttir, K. Á., Olsen, K. E., Mouridsen, H. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.007 · Cited by 320 · see citing works
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
Chin, S., Teschendorff, A. E., Marioni, J. C., Wang, Y., Barbosa‐Morais, N. L., Thorne, N., Costa, J. L., Pinder, S. E., van de Wiel, M. A., Green, A. R., et al. (2007) · Genome biology · doi:10.1186/gb-2007-8-10-r215 · Cited by 320 · see citing works
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Kwan, M. L., Kushi, L. H., Weltzien, E. K., Maring, B., Kutner, S. E., Fulton, R. S., Lee, M. M., Ambrosone, C. B., & Caan, B. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2261 · Cited by 318 · see citing works
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
Tan, D. S. P., Marchiò, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318 · see citing works
Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling
Swameye, I., Müller, T. G., Timmer, J., Sandra, O., & Klingmüller, U. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237333100 · Cited by 316 · see citing works
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation
Rakha, E. A., Putti, T. C., El-Rehim, D. A., Paish, C. E., Green, A. R., Powe, D. G., Lee, A. H., Robertson, J., & Ellis, I. O. (2006) · The Journal of Pathology · doi:10.1002/path.1916 · Cited by 311 · see citing works
Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers
Bertucci, F., Finetti, P., Cervera, N., Charafe‐Jauffret, E., Mamessier, É., Adélaı̈de, J., Debono, S., Houvenaeghel, G. F., Maraninchi, D., Viens, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0031 · Cited by 308 · see citing works
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307 · see citing works
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Burgess, D. J., Doles, J. D., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803513105 · Cited by 302 · see citing works
Breast tumor copy number aberration phenotypes and genomic instability
Fridlyand, J., Snijders, A. M., Ylstra, B., Li, H., Olshen, A. B., Segraves, R., Dairkee, S. H., Tokuyasu, T. A., Ljung, B., Jain, A. N., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-96 · Cited by 298 · see citing works
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen‐Dale, A., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291 · see citing works
Self-citation
Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
Bosch, A., Eroles, P., Zaragozá, R., Vinã, J. R., & Lluch, A. M. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.002 · Cited by 281 · see citing works
Diffusion-weighted MR for Differentiation of Breast Lesions at 3.0 T: How Does Selection of Diffusion Protocols Affect Diagnosis?
Bogner, W., Gruber, S., Pinker, K., Grabner, G., Stadlbauer, A., Weber, M., Moser, E., Helbich, T. H., & Trattnig, S. (2009) · Radiology · doi:10.1148/radiol.2532081718 · Cited by 278 · see citing works
Molecular insights into human daily behavior
Brown, S. A., Kunz, D., Dumas, A., Westermark, P. O., Vanselow, K., Tilmann-Wahnschaffe, A., Herzel, H., & Kramer, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707772105 · Cited by 270 · see citing works
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Dowsett, M., & Dunbier, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0974 · Cited by 269 · see citing works
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266 · see citing works
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
Calza, S., Hall, P. N., Auer, G., Bjöhle, J., Klaar, S., Kronenwett, U., Liu, E. T., Miller, L. D., Ploner, A., Smeds, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1517 · Cited by 263 · see citing works
Review: Hypoxia-Inducible Factor-1 (HIF-1): A Novel Transcription Factor in Immune Reactions
Hellwig‐Bürgel, T., Stiehl, D. P., Wagner, A. E., Metzen, E., & JELKMANN, W. E. B. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.297 · Cited by 255 · see citing works
Triple-negative breast cancers are increased in black women regardless of age or body mass index
Stead, L. A., Lash, T. L., Sobieraj, J. E., Dorcas, D. J., Westrup, J., Charlot, M., Blanchard, R. A., Lee, J. C., King, T. C., & Rosenberg, C. L. (2009) · Breast Cancer Research · doi:10.1186/bcr2242 · Cited by 250 · see citing works
Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parameters
Basu, S. K., Chen, W., Tchou, J. C., Mavi, A., Çermik, T. F., Czerniecki, B. J., Schnall, M. D., & Alavi, A. A. (2007) · Cancer · doi:10.1002/cncr.23226 · Cited by 248 · see citing works
Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications
Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., & Leo, A. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7550 · Cited by 245 · see citing works
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
O’Shaughnessy, J., Osborne, C. R. C., Pippen, J., Yoffe, M., Patt, D. A., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B. M., & Bradley, C. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3 · Cited by 242 · see citing works
Regulatory gene networks and the properties of the developmental process
Davidson, E. H., McClay, D. R., & Hood, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437746100 · Cited by 238 · see citing works
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis
Weigelt, B., Kreike, B., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0197-9 · Cited by 224 · see citing works
Systems-level interactions between insulin–EGF networks amplify mitogenic signaling
Borisov, N., Aksamitiene, E., Kiyatkin, A., Legewie, S., Berkhout, J., Maiwald, T., Kaimachnikov, N. P., Timmer, J., Hoek, J. B., & Kholodenko, B. N. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.19 · Cited by 222 · see citing works
Platinum-based chemotherapy in triple-negative breast cancer
Sirohi, B., Arnedos, M., Popat, S., Ashley, S. E., Nerurkar, A. Y., Walsh, G., Johnston, S. R. D., & Smith, I. E. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn395 · Cited by 220 · see citing works
A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors
Collett, K., Stefansson, I. M., Eide, J., Braaten, A. O., Wang, H., Eide, G. E., Thoresen, S., Foulkes, W. D., & Akslen, L. A. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0394 · Cited by 215 · see citing works
MicroRNAs Differentially Regulated by Akt Isoforms Control EMT and Stem Cell Renewal in Cancer Cells
Iliopoulos, D., Polytarchou, C., Hatziapostolou, M., Kottakis, F., Maroulakou, I. G., Struhl, K., & Tsichlis, P. N. (2009) · Science Signaling · doi:10.1126/scisignal.2000356 · Cited by 206 · see citing works
Typical medullary breast carcinomas have a basal/myoepithelial phenotype
Jacquemier, J. D., Padovani, L., Rabayrol, L., Lakhani, S. R., Penault-Llorca, F. M., Denoux, Y., Fiche, M., Figueiro, P., Maisongrosse, V., Doussal, V. L., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1845 · Cited by 202 · see citing works
Origins of breast cancer subtypes and therapeutic implications
Sims, A. H., Howell, A., Howell, S. J., & Clarke, R. B. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0908 · Cited by 198 · see citing works
Mathematical modeling identifies Smad nucleocytoplasmic shuttling as a dynamic signal-interpreting system
Schmierer, B., Tournier, A., Bates, P. A., & Hill, C. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710134105 · Cited by 191 · see citing works
The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data
Samaga, R., Sáez-Rodríguez, J., Alexopoulos, L. G., Sorger, P. K., & Klamt, S. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000438 · Cited by 191 · see citing works
Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
Viale, G., Rotmensz, N., Maisonneuve, P., Bottiglieri, L., Montagna, E., Luini, A., Veronesi, P., Intra, M., Torrisi, R., Cardillo, A., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0206-z · Cited by 189 · see citing works
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
Vincent‐Salomon, A., Gruel, N., Lucchesi, C., MacGrogan, G. M., Dendale, R., Sigal‐Zafrani, B., Longy, M., Raynal, V., Pierron, G., de Mascarel, I., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1666 · Cited by 187 · see citing works
BRCA1 functions as a breast stem cell regulator
Foulkes, W. D. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.013805 · Cited by 184 · see citing works
p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding
Liu, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.851 · Cited by 183 · see citing works
Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers
Woo, H. M., Kim, K. M., Choi, M. H., Jung, B. H., Lee, J., Kong, G., Nam, S. J., Kim, S., Bai, S. W., & Chung, B. C. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.10.014 · Cited by 182 · see citing works
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios, J., Honrado, E., Osório, A., Cazorla, A., Sarrió, D., Barroso, A., Rodríguez, S., Cigudosa, J. C., Dı́ez, O., Alonso, C., et al. (2003) · PubMed · Cited by 175 · see citing works
The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis
Lucas, K. G., Brown, A. E., Armstrong, D., Chapman, D. S., & Heller, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4 · Cited by 174 · see citing works
The relationship between prognostic and predictive factors in the management of breast cancer
Henderson, I., & Patek, A. (2004) · Breast Cancer Research and Treatment · doi:10.1023/a:1006141703224 · Cited by 171 · see citing works
Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Eisinger, F., Stoppa‐Lyonnet, D., Longy, M., Kerangueven, F., Noguchi, T., Bailly, C., Vincent‐Salomon, A., Jacquemier, J. D., Birnbaum, D., & Sobol, H. (1996) · PubMed · Cited by 171 · see citing works
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
Carey, L., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., He, X., Perou, C. M., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1009 · Cited by 163 · see citing works
Cell biology of the movement of breast cancer cells: Intracellular signalling and the actin cytoskeleton
Jiang, P., Enomoto, A., & Takahashi, M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.034 · Cited by 163 · see citing works
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome
Azoulay, S., Lae, M. E., Fréneaux, P., Merle, S., Ghuzlan, A. A., Chnecker, C., Rosty, C., Klijanienko, J., Sigal‐Zafrani, B., Salmon, R. J., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800483 · Cited by 162 · see citing works
A network biology approach to prostate cancer
Ergün, A., Lawrence, C. A., Kohanski, M. A., Brennan, T. A., & Collins, J. J. (2007) · Molecular Systems Biology · doi:10.1038/msb4100125 · Cited by 161 · see citing works
Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women
Yang, W. T., Dryden, M. J., Broglio, K. R., Gilcrease, M. Z., Dawood, S. S., Dempsey, P. J., Valero, V., Hortobágyi, G. N., Atchley, D. P., & Arun, B. K. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9810-6 · Cited by 157 · see citing works
Estrogen Receptor–Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression
Wang, Y., Ikeda, D. M., Narasimhan, B., Longacre, T. A., Bleicher, R. J., Pal, S., Jackman, R. J., & Jeffrey, S. S. (2008) · Radiology · doi:10.1148/radiol.2462070169 · Cited by 157 · see citing works
Neural Networks and Pattern Recognition
(1998) · Elsevier eBooks · doi:10.1016/b978-0-12-526420-4.x5000-9 · Cited by 156 · see citing works
Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification
Nam, H., Chung, B. C., Kim, Y.-H., Lee, K., & Lee, D. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp558 · Cited by 154 · see citing works
Survival and prognostic factors in BRCA1-associated breast cancer.
Brekelmans, C., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H., Tilanus-Linthorst, M., Bartels, C., Kriege, M., van Geel, A. V., Crepin, C., Blom, J., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 147 · see citing works
A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response
Chandriani, S., Frengen, E., Cowling, V., Pendergrass, S., Perou, C., Whitfield, M., & Cole, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006693 · Cited by 145 · see citing works
A Computational Model for Understanding Stem Cell, Trophectoderm and Endoderm Lineage Determination
Chickarmane, V. S., & Peterson, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003478 · Cited by 143 · see citing works
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Naume, B., Zhao, X., Synnestvedt, M., Borgen, E., Russnes, H. G., Lingjærde, O. C., Strømberg, M., Wiedswang, G., Kvalheim, G., Kåresen, R., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.03.004 · Cited by 143 · see citing works
Self-citation
Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells
Furuta, S., Jiang, X., Gu, B., Cheng, E., Chen, P., & Lee, W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503793102 · Cited by 140 · see citing works
The prognostic importance of triple negative breast carcinoma
Mersin, H., Yıldırım, E., Berberoğlu, U., & Gülben, K. (2008) · The Breast · doi:10.1016/j.breast.2007.11.031 · Cited by 138 · see citing works
Multiproject–multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy
Garcia-Gomez, J. M., Luts, J., Julià‐Sapé, M., Krooshof, P. W. T., Tortajada, S., Vicente, J., Melssen, W. J., Fuster‐García, E., Olier, I., Postma, G., et al. (2008) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-008-0146-y · Cited by 136 · see citing works
Self-citation
MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status
Bathen, T. F., Jensen, L. R., Sitter, B., Fjøsne, H. E., Halgunset, J., Axelson, D. E., Gribbestad, I. S., & Lundgren, S. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9400-z · Cited by 133 · see citing works
Self-citation
Multivariate Modeling and Prediction of Breast Cancer Prognostic Factors Using MR Metabolomics
Giskeødegård, G. F., Grinde, M. T., Sitter, B., Axelson, D. E., Lundgren, S., Fjøsne, H. E., Dahl, S., Gribbestad, I. S., & Bathen, T. F. (2009) · Journal of Proteome Research · doi:10.1021/pr9008783 · Cited by 128 · see citing works
Self-citation
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
(1997) · PubMed · Cited by 121 · see citing works
Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Møller, P., Borg, Å., Evans, D. G., Kingsbury, N., Reis, M. M., Vasen, H. F. A., Anderson, E. D. C., Steel, C. M., Apold, J., Goudie, D. R., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10641 · Cited by 113 · see citing works
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga, J. M., Zambetti, M., Llombart‐Cussac, A., Manikhas, G., Kubista, E., Steger, G. G., Makhson, A. N., Tjulandin, S., Ludwig, H., Verrill, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2646 · Cited by 112 · see citing works
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations
Honrado, E., Osório, A., Palacios, J., & Benitez, J. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209875 · Cited by 108 · see citing works
Overview of tyrosine kinase inhibitors in clinical breast cancer
Agrawal, A., Gutteridge, E., Gee, J. M. W., Nicholson, R. I., & Robertson, J. F. R. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01059 · Cited by 104 · see citing works
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1‐related breast carcinoma
Foulkes, W. D., Metcalfe, K. A., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B., McLennan, J., Olivotto, I. A., et al. (2003) · Cancer · doi:10.1002/cncr.11688 · Cited by 103 · see citing works
‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity?
Japaze, H., Emina, J., Diaz, C., Schwam, R. J., Gercovich, N., Demonty, G., Morgenfeld, E. L., Rivarola, E. G. J., Deza, E. G., & Gercovich, F. G. (2004) · The Breast · doi:10.1016/j.breast.2004.06.003 · Cited by 97 · see citing works
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status
Møller, P., Evans, D. G., Reis, M. M., Gregory, H., Anderson, E. D. C., Mæhle, L., Lalloo, F. I., Howell, A., Apold, J., Clark, N., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22789 · Cited by 95 · see citing works
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
O’Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D. A., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B. M., & Bradley, C. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.3 · Cited by 95 · see citing works
High-resolution magic angle spinning (HR MAS) MR spectroscopy in metabolic characterization of human cancer
Sitter, B., Bathen, T. F., Tessem, M.-B., & Gribbestad, I. S. (2009) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2008.10.001 · Cited by 91 · see citing works
Self-citation
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko, T. A., Blackwood, M. A., Schumm, L. P., Hagos, F., Adeyanju, M., Feldman, M. D., Sanders, M. O., Weber, B. L., & Olopade, O. I. (2002) · PubMed · Cited by 90 · see citing works
T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy
Kaplan, H. G., Malmgren, J. A., & Atwood, M. K. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00789.x · Cited by 89 · see citing works
Clinical proteomics in breast cancer: a review
Gast, M. W., Schellens, J. H. M., & Beijnen, J. H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0263-3 · Cited by 89 · see citing works
Constraint-Based Modeling and Kinetic Analysis of the Smad Dependent TGF-β Signaling Pathway
Zi, Z., & Klipp, E. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000936 · Cited by 87 · see citing works
Self-citation
Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer
Belluco, C., Petricoin, E. F., Mammano, E., Facchiano, F., Ross-Rucker, S., Nitti, D., Maggio, C. C. D., Liu, C., Lise, M., Liotta, L. A., et al. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9354-3 · Cited by 86 · see citing works
BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer
Gorski, J. J., James, C. R., Quinn, J. E., Stewart, G. E., Crosbie-Staunton, K., Buckley, N. E., McDyer, F. A., Kennedy, R. D., Wilson, R. H., Mullan, P. B., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0565-0 · Cited by 82 · see citing works
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan, P. D., Tung, N., Isakoff, S. J., Golshan, M. A., Richardson, A., Corben, A. D., Smith, B. L., Gelman, R. S., Winer, E. P., & Garber, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.551 · Cited by 82 · see citing works
Role of BRCAgene dysfunction in breast and ovarian cancer predisposition
Scully, R. (2000) · Breast Cancer Research · doi:10.1186/bcr76 · Cited by 78 · see citing works
Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection
Henneges, C., Bullinger, D., Fux, R., Friese, N., Seeger, H., Neubauer, H. J., Laufer, S., Gleiter, C. H., Schwab, M. G., Zell, A., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-104 · Cited by 78 · see citing works
Therapeutic Strategies for Triple-Negative Breast Cancer
Tan, A. R., & Swain, S. M. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31818d839b · Cited by 76 · see citing works
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
Bild, A. H., Parker, J. S., Gustafson, A. M., Acharya, C. R., Hoadley, K. A., Anders, C. K., Marcom, P. K., Carey, L., Potti, A., Nevins, J. R., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2344 · Cited by 75 · see citing works
Triple-negative breast cancer: MRI features in 29 patients
Chen, J.-H., Agrawal, G., Feig, B., Baek, H., Carpenter, P. M., Nalcioglu, O., Su, M., & Mehta, R. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm504 · Cited by 75 · see citing works
External Validation of Mathematical Models to Distinguish Between Benign and Malignant Adnexal Tumors: A Multicenter Study by the International Ovarian Tumor Analysis Group
Holsbeke, C. V., CALSTER, B. V., Valentin, L., Testa, A. C., Ferrazzi, E. M., Dimou, I. N., Lü, C., Moerman, P., Huffel, S. V., Vergote, I. B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2958 · Cited by 75 · see citing works
Molecular classification of solid tumours: towards pathway-driven therapeutics
Swanton, C., & Caldas, C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605031 · Cited by 71 · see citing works
Basal-like Breast Carcinoma: A Phenotypically Distinct Entity
Haupt, B., Ro, J. Y., & Schwartz, M. R. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.1.130 · Cited by 66 · see citing works
Histoprognostic grade in BRCA1-associated breast cancer
Jacquemier, J. D., Eisinger, F., Birnbaum, D., & Sobol, H. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91060-3 · Cited by 63 · see citing works
Triple-negative breast cancer
Stockmans, G., Deraedt, K., Wildiers, H. P. M. W., Moerman, P., & Paridaens, R. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328312efba · Cited by 63 · see citing works
Brca1 regulates in vitro differentiation of mammary epithelial cells
Kubista, M., Rosner, M., Kubista, E., BERNASCHEK, G., & Hengstschläger, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205580 · Cited by 62 · see citing works
The ?portrait? of hereditary breast cancer
Lacroix, M., & Leclercq, G. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-2172-4 · Cited by 62 · see citing works
MYC amplification in breast cancer: a chromogenic in situ hybridisation study
Rodríguez-Pinilla, S. M., Jones, R. L., Lambros, M. B. K., Arriola, E., Savage, K., James, M., Pinder, S. E., & Reis-Filho, J. S. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043869 · Cited by 59 · see citing works
Integrating Biological Knowledge with Gene Expression Profiles for Survival Prediction of Cancer
Chen, X., & Wang, L. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.12tt · Cited by 58 · see citing works
Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Podo, F., Sardanelli, F., Iorio, E., Canese, R., Carpinelli, G., Fausto, A., & Canevari, S. (2007) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/157340507780619160 · Cited by 58 · see citing works
Self-citation
An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes
Melchor, L., & Benitez, J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn157 · Cited by 58 · see citing works
Agent Technology and e-Health
Annicchiarico, R., Urdiales, C., & CortÃ©s, U. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8547-7 · Cited by 57 · see citing works
c- myc Amplifications in primary breast carcinomas and their local recurrences
Aulmann, S., Adler, N., Rom, J., Helmchen, B., Schirmacher, P., & Sinn, H. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.029264 · Cited by 56 · see citing works
A systems biological approach suggests that transcriptional feedback regulation by dual‐specificity phosphatase 6 shapes extracellular signal‐related kinase activity in RAS‐transformed fibroblasts
Blüthgen, N., Legewie, S., Kiełbasa, S. M., Schramme, A., Tchernitsa, O. I., Keil, J., Solf, A., Vingron, M., Schäfer, R., Herzel, H., et al. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06846.x · Cited by 55 · see citing works
The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma
Corzo, C., Corominas, J. M., Tusquets, I., Salido, M., Bellet, M., Fabregat, X., Serrano, S., & Solé, F. G. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.08.013 · Cited by 53 · see citing works
Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment
Bouchalová, K., Čížková, M., Cwiertka, K., Trojanec, R., & Hajdúch, M. (2009) · Biomedical Papers · doi:10.5507/bp.2009.002 · Cited by 53 · see citing works
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review
Bonadona, V., Dussart, S., Voirin, N., Sinilnikova, O. M., Mignotte, H., Mathevet, P., Bremond, A. G., Treilleux, I., Martin, A., Romestaing, P., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9288-7 · Cited by 51 · see citing works
Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families
Honrado, E., Osório, A., Milne, R. L., Paz, M. F., Melchor, L., Cascón, A., Urioste, M., Cazorla, A., Dı́ez, O., Lerma, E., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800969 · Cited by 50 · see citing works
Report on EU–USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008)
Aebersold, R. H., Auffray, C., Baney, E., Barillot, E., Brāzma, A., Brett, C., Brunak, S., Butte, A. J., Califano, A., Celis, J. E., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.11.003 · Cited by 42 · see citing works
Magnetic Resonance Spectroscopic Imaging of Tumor Metabolic Markers for Cancer Diagnosis, Metabolic Phenotyping, and Characterization of Tumor Microenvironment
He, Q., Xu, R. Z., Shkarin, P., Pizzorno, G., Lee-French, C. H., Rothman, D. L., Shungu, D. C., & Shim, H. (2004) · Disease Markers · doi:10.1155/2004/424395 · Cited by 42 · see citing works
Portraits of breast cancer progression
Dalgin, G. S., Alexe, G., Scanfeld, D., Tamayo, P., Mesirov, J. P., Ganesan, S., DeLisi, C., & Bhanot, G. V. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-291 · Cited by 41 · see citing works
Towards a systems biology approach to mammalian cell cycle: modeling the entrance into S phase of quiescent fibroblasts after serum stimulation
Alfieri, R. R., Barberis, M., Chiaradonna, F., Gaglio, D., Milanesi, L., Vanoni, M., Klipp, E., & Alberghina, L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s12-s16 · Cited by 39 · see citing works
Self-citation
Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy.
von Minckwitz, G., Kaufmann, M., Kümmel, S., Fasching, P. A., EIERMANN, W., Blohmer, J., Costa, S., Loibl, S., Dietmar, V., & Untch, M. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-79 · Cited by 37 · see citing works
Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites
Durbecq, V., Leo, A. D., Cardoso, F., Rouas, G., Leroy, J.-Y., Piccart, M. J., & Larsimont, D. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1021874224490 · Cited by 31 · see citing works

Flagged first, then by citations

2 of the 215 references couldn’t be matched to a known paper.

Sorted by citations

Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,345 · see citing works
Histological types of breast cancer: How special are they?
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.004 · Cited by 572 · see citing works
Genetic susceptibility to breast cancer
Mavaddat, N., Antoniou, A. C., Easton, D. F., & García‐Closas, M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.011 · Cited by 376 · see citing works
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 289 · see citing works
Patient-derived xenograft models of breast cancer and their predictive power
Whittle, J. R., Lewis, M. T., Lindeman, G. J., & Visvader, J. E. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0523-1 · Cited by 280 · see citing works
Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer
Sebastian, A., Hum, N. R., Martin, K. A., Gilmore, S. F., Peran, I., Byers, S. W., Wheeler, E. K., Coleman, M. A., & Loots, G. G. (2020) · Cancers · doi:10.3390/cancers12051307 · Cited by 263 · see citing works
Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes
Youk, J. H., Son, E. J., Chung, J. I., Kim, J., & Kim, E. (2012) · European Radiology · doi:10.1007/s00330-012-2425-2 · Cited by 222 · see citing works
PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA
Tan, L., Mai, D., Zhang, B., Jiang, X., Zhang, J., Bai, R., Ye, Y., Li, M., Pan, L., Su, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0940-3 · Cited by 205 · see citing works
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Agostino, S. D. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 198 · see citing works
Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31764-9 · Cited by 200 · see citing works
MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer
Ouyang, M., Li, Y., Ye, S., Ma, J., Lu, L., Lv, W., Chang, G., Li, X., Li, Q., Wang, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096228 · Cited by 195 · see citing works
Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
McGhan, L. J., McCullough, A. E., Protheroe, C. A., Dueck, A. C., Lee, J. J., Núñez-Nateras, R., Castle, E. P., Gray, R. J., Wasif, N., Goetz, M. P., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3260-7 · Cited by 168 · see citing works
C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer.
Wang, O., Yang, F., Liu, Y., Lv, L., Ma, R., Chen, C., Wang, J., Tan, Q., Cheng, Y., Xia, E., et al. (2017) · Europe PMC (PubMed Central) · Cited by 159 · see citing works
Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells
Burnett, J., Lim, G., Li, Y., Shah, R. B., Lim, R., Paholak, H. J., McDermott, S., Sun, L., Tsume, Y., Bai, S., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.023 · Cited by 156 · see citing works
Genomic instability in breast cancer: Pathogenesis and clinical implications
Kwei, K. A., Kung, Y., Salari, K., Holcomb, I. N., & Pollack, J. R. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.001 · Cited by 151 · see citing works
Tracing the tumor lineage
Navin, N. E., & Hicks, J. B. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.010 · Cited by 148 · see citing works
LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer
Luo, L., Tang, H., Li, L., Li, N., Jia, X., Zhang, Z., Wang, X., Shi, L., Yin, J., Qiu, N., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0396-8 · Cited by 146 · see citing works
Combination antitumor therapy with targeted dual-nanomedicines
Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 139 · see citing works
In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development
Ozerov, I. V., Lezhnina, K. V., Izumchenko, E., Artemov, A. V., Medintsev, S., Vanhaelen, Q., Aliper, A. M., Vijg, J., Osipov, A. N., Labat, I., et al. (2016) · Nature Communications · doi:10.1038/ncomms13427 · Cited by 136 · see citing works
El cáncer de mama en el siglo XXI: de la detección precoz a los nuevos tratamientos
Bonilla, J., Tabanera, M. T., & Mendoza, L. H. R. (2017) · Radiología · doi:10.1016/j.rx.2017.06.003 · Cited by 132 · see citing works
Breast cancer in the 21st century: From early detection to new therapies
Bonilla, J., Tabanera, M. T., & Mendoza, L. H. R. (2017) · Radiología (English Edition) · doi:10.1016/j.rxeng.2017.08.001 · Cited by 123 · see citing works
Hybrid Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Modulating Tumor Hypoxia
Abbasi, A. Z., Gordijo, C. R., Amini, M. A., Maeda, A., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3475 · Cited by 121 · see citing works
Nanoparticles for imaging and treatment of metastatic breast cancer
Mu, Q.-X., Wang, H., & Zhang, M.-Q. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1208650 · Cited by 100 · see citing works
Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells
Ravi, M., Tentu, S., Baskar, G., Surabhi, R. P., Raghavan, S., Jayaprakash, P., Jeyakanthan, J., Rayala, S. K., & Venkatraman, G. (2015) · BMC Cancer · doi:10.1186/s12885-015-1784-x · Cited by 115 · see citing works
Distant metastasis in triple-negative breast cancer
Tseng, L., Hsu, N., Chen, S.-C., Lu, Y., Lin, C., CHANG, D. Y., LI, H., LIN, Y. C., CHANG, H. K., Chao, T., et al. (2013) · Neoplasma · doi:10.4149/neo_2013_038 · Cited by 113 · see citing works
Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer
Jusu, S. M., Obayemi, J. D., Salifu, A. A., Nwazojie, C. C., Uzonwanne, V., Odusanya, O. S., & Soboyejo, W. O. (2020) · Scientific Reports · doi:10.1038/s41598-020-71129-0 · Cited by 112 · see citing works
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study
Fostira, F., Tsitlaidou, M., PAPADIMITRIOU, C. A., Pertesi, M., Timotheadou, E. T., Stavropoulou, A. V., Glentis, S., Bournakis, E., Bobos, M., Pectasides, D. G., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2021-9 · Cited by 107 · see citing works
Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
Dai, W., Yang, F., Ma, L., Fan, Y., He, B., He, Q., Wang, X., Zhang, H., & Zhang, Q. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.036 · Cited by 104 · see citing works
Targeting DNA Replication Stress for Cancer Therapy
Zhang, J., Dai, Q., Park, D., & Deng, X. (2016) · Genes · doi:10.3390/genes7080051 · Cited by 102 · see citing works
Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells
Dandawate, P. R., Khan, E. M., Padhyé, S., Gaba, H., Sinha, S., Deshpande, J., Swamy, K. V., Khetmalas, M. B., Ahmad, A., & Sarkar, F. H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.060 · Cited by 101 · see citing works
A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer
Singel, S. M., Cornelius, C., Batten, K. G., Fasciani, G., Wright, W. E., Lum, L., & Shay, J. W. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0082 · Cited by 99 · see citing works
Machine Learning for Precision Breast Cancer Diagnosis and Prediction of the Nanoparticle Cellular Internalization
Alafeef, M., Srivastava, I., & Pan, D. (2020) · ACS Sensors · doi:10.1021/acssensors.0c00329 · Cited by 99 · see citing works
Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells
Yi, Y. W., Kang, H. J., Kim, H. J., Kong, Y., Brown, M. L., & Bae, I. (2013) · Oncotarget · doi:10.18632/oncotarget.1070 · Cited by 93 · see citing works
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer
Avery‐Kiejda, K. A., Braye, S. G., Mathe, A., Forbes, J., & Scott, R. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-51 · Cited by 91 · see citing works
Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells
Yang, F., Wang, F., Liu, Y., Wang, S., Li, X., Huang, Y., Xia, Y., & Cao, C. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.034 · Cited by 90 · see citing works
miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer
Yan, M., Li, X., Tong, D., Han, C., Zhao, R., He, Y., & Jin, X. (2016) · Oncology Reports · doi:10.3892/or.2016.4767 · Cited by 84 · see citing works
The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome
Avery‐Kiejda, K. A., Morten, B. C., Wong‐Brown, M. W., Mathe, A., & Scott, R. J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt411 · Cited by 83 · see citing works
Novel prognostic and predictive microRNA targets for triple‐negative breast cancer
Turashvili, G., Lightbody, E. D., Tyryshkin, K., Sengupta, S., Elliott, B. E., Madarnas, Y., Ghaffari, A., Day, A. G., & Nicol, C. J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201800120r · Cited by 82 · see citing works
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer
Samuel, S., Varghese, E., Kubatka, P., Triggle, C., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120846 · Cited by 81 · see citing works
MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1
Hulin, J.-A., Tommasi, S., Elliot, D. J., Hu, D. G., Lewis, B. C., & Mangoni, A. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14454-1 · Cited by 80 · see citing works
RETRACTED: Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles
Das, S., Mukherjee, P., Chatterjee, R., Jamal, Z., & Chatterji, U. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0409 · Cited by 79 · see citing works
Retracted
Panepoxydone Targets NF-kB and FOXM1 to Inhibit Proliferation, Induce Apoptosis and Reverse Epithelial to Mesenchymal Transition in Breast Cancer
Arora, R., Yates, C. C., Gary, B. D., McClellan, S. B., Tan, M., Xi, Y., Reed, E., Piazza, G. A., Owen, L. B., & Dean-Colomb, W. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098370 · Cited by 77 · see citing works
Retracted
Phage Display Technology as a Powerful Platform for Antibody Drug Discovery
Nagano, K., & Tsutsumi, Y. M. (2021) · Viruses · doi:10.3390/v13020178 · Cited by 76 · see citing works
Inhibition of the PI 3K/ AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple‐negative breast cancer cells
Yi, Y. W., Hong, W., Kang, H. J., Kim, H. J., Zhao, W., Wang, A., Seong, Y., & Bae, I. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12046 · Cited by 76 · see citing works
mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors
Walsh, S., Flanagan, L., Quinn, C., Evoy, D., McDermott, E. W. M., Pierce, A., & Duffy, M. J. (2011) · The Breast · doi:10.1016/j.breast.2011.09.008 · Cited by 73 · see citing works
Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
Narayanan, R., Ahn, S., Cheney, M. D., Yepuru, M., Miller, D. D., Steiner, M. S., & Dalton, J. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103202 · Cited by 71 · see citing works
Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model
Singh, U., Chashoo, G., Khan, S. U., Mahajan, P., Nargotra, A., Mahajan, G., Singh, A., Sharma, A., Mintoo, M. J., Guru, S. K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00663 · Cited by 69 · see citing works
Prognostic value of LINE-1 retrotransposon expression and its subcellular localization in breast cancer
Chen, L., Dahlstrom, J. E., Chandra, A., Philip G. Board, & Rangasamy, D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2246-7 · Cited by 68 · see citing works
Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA
Zhang, Q., Li, L., & Jing, D. (2020) · Oncology Reports · doi:10.3892/or.2020.7770 · Cited by 66 · see citing works
Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways
Lim, E. J., Hong, D. Y., Park, J. H., Joung, Y. H., Darvin, P., Kim, S. Y., Na, Y. M., Hwang, T. S., Ye, S., Moon, E.-S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033361 · Cited by 66 · see citing works
Icariside II inhibits the EMT of NSCLC cells in inflammatory microenvironment via down-regulation of Akt/NF-κB signaling pathway
Song, J., Feng, L., Zhong, R., Xia, Z., Zhang, L. R., Cui, L., Yan, H., Jia, X., & Zhang, Z. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22471 · Cited by 64 · see citing works
Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing
Wu, H., Wang, Q., Zhong, H., Li, L., Zhang, Q., Huang, Q., & Yu, Z. (2019) · Oncology Reports · doi:10.3892/or.2019.7401 · Cited by 62 · see citing works
Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype
Pacheco-Velázquez, S. C., Robledo‐Cadena, D. X., Hernández‐Reséndiz, I., Gallardo‐Pérez, J. C., Moreno‐Sánchez, R., & Rodríguez‐Enríquez, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00015 · Cited by 62 · see citing works
Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
Chun, K., Park, J. H., & Fan, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_4 · Cited by 59 · see citing works
Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
Iorio, E., Caramujo, M.-J., Cecchetti, S., Spadaro, F., Carpinelli, G., Canese, R., & Podo, F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00205 · Cited by 61 · see citing works
Self-citation
Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene
Yan, Y., Li, X., Duan, J., Bao, C., Cui, Y., Su, Z.-B., Xu, J., Luo, Q., Chen, M., Xie, Y., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s207837 · Cited by 59 · see citing works
Interleukin‐6 contributes to chemoresistance in MDA‐MB‐231 cells via targeting HIF‐1α
Wang, K., Zhu, X., Zhang, K., Yin, Y., Chen, Y., & Zhang, T. (2018) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22039 · Cited by 59 · see citing works
Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression
Anderson, T. M. R., Peacock, D. L., Daniel, A. R., Hubbard, G. K., Lofgren, K. A., Girard, B. J., Schörg, A., Hoogewijs, D., Wenger, R. H., Seagroves, T. N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0523 · Cited by 58 · see citing works
Novel genes associated with lymph node metastasis in triple negative breast cancer
Mathe, A., Wong‐Brown, M. W., Morten, B. C., Forbes, J., Braye, S. G., Avery‐Kiejda, K. A., & Scott, R. J. (2015) · Scientific Reports · doi:10.1038/srep15832 · Cited by 58 · see citing works
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
Fleisher, B., Clarke, C. H., & Ait‐Oudhia, S. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s114659 · Cited by 58 · see citing works
NF-κB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers
Poma, P., Labbozzetta, M., D’Alessandro, N., & Notarbartolo, M. (2017) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0020 · Cited by 58 · see citing works
Investigation of adhesive interactions in the specific targeting of Triptorelin-conjugated PEG-coated magnetite nanoparticles to breast cancer cells
Hu, J., Youssefian, S., Obayemi, J. D., Malatesta, K. A., Rahbar, N., & Soboyejo, W. O. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.02.011 · Cited by 57 · see citing works
The genetics of breast cancer: risk factors for disease
Collins, A. R. (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s13139 · Cited by 57 · see citing works
Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion
JavanMoghadam, S., Weihua, Z., Hunt, K. K., & Keyomarsi, K. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1166327 · Cited by 55 · see citing works
Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer.
Zhu, H., Bhaijee, F., Ishaq, N. Y., Pepper, D. J., Backus, K. V., Brown, A. S., Zhou, X., & Miele, L. (2013) · Europe PMC (PubMed Central) · Cited by 54 · see citing works
Inhibition of cross-species CXCR4 signaling by the small molecule IT1t impairs triple negative breast cancer early metastases in zebrafish
Tulotta, C., Stefanescu, C., Beletkaia, E., Bussmann, J., Tarbashevich, K., Schmidt, T., & Snaar-Jagalska, E. B. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.023275 · Cited by 54 · see citing works
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
Bakrania, A. K., Variya, B. C., & Patel, S. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.023 · Cited by 53 · see citing works
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
Ruan, M., Tian, T., Rao, J., Xu, X., Yu, B., Yang, W., & Shui, R. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0743-7 · Cited by 53 · see citing works
Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells
Kim, S., Lee, J., Jeon, M., Nam, S. J., & Lee, J. E. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.020 · Cited by 53 · see citing works
MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2
Tang, W., Xu, P., Wang, H., Niu, Z., Zhu, D., Qi, L., Tang, L., & Ren, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161996 · Cited by 51 · see citing works
Machine learning analysis identifies genes differentiating triple negative breast cancers
Kothari, C., Osseni, M. A., Agbo, L., Ouellette, G., Déraspe, M., Laviolette, F., Corbeil, J., Lambert, J., Diorio, C., & Durocher, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-67525-1 · Cited by 50 · see citing works
Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
Pradhan, R., Dey, A., Taliyan, R., Puri, A., Kharavtekar, S. S., & Dubey, S. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010246 · Cited by 50 · see citing works
Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers
Nagano, K., Maeda, Y., Kanasaki, S., Watanabe, T., Yamashita, T., Inoue, M., Higashisaka, K., Yoshioka, Y., Abe, Y., Mukai, Y., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.010 · Cited by 50 · see citing works
Understanding the cancer cell phenotype beyond the limitations of current omics analyses
Moreno‐Sánchez, R., Saavedra, E., Gallardo‐Pérez, J. C., Rumjanek, F. D., & Rodríguez‐Enríquez, S. (2015) · FEBS Journal · doi:10.1111/febs.13535 · Cited by 50 · see citing works
Triple negative breast cancer: new therapeutic approaches and BRCA status
Eskiler, G. G., Çeçener, G., Egelí, Ü., & Tunca, B. (2018) · Apmis · doi:10.1111/apm.12836 · Cited by 49 · see citing works
DDR1 promotes breast tumor growth by suppressing antitumor immunity
Zhong, X., Zhang, W., & Sun, T. (2019) · Oncology Reports · doi:10.3892/or.2019.7338 · Cited by 49 · see citing works
Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer
Pern, F., Bogdanova, N. V., Schürmann, P., Lin, M., Ay, A., Länger, F. P., Hillemanns, P., Christiansen, H., Park‐Simon, T., & Dörk, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047993 · Cited by 48 · see citing works
Influence of washing and quenching in profiling the metabolome of adherent mammalian cells: a case study with the metastatic breast cancer cell line MDA-MB-231
Kapoore, R. V., Coyle, R., Staton, C. A., Brown, N. J., & Vaidyanathan, S. (2017) · The Analyst · doi:10.1039/c7an00207f · Cited by 48 · see citing works
Triple Negative Breast Cancer
Çeti̇n, İ., & Topçul, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.6.2427 · Cited by 46 · see citing works
Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Romanelli, A., Clark, A., Assayag, F., Château‐Joubert, S., Poupon, M., Servely, J., Fontaine, J., Liu, X., Spooner, E., Goodstal, S. M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0441-t · Cited by 46 · see citing works
Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway
Kim, S., Lee, J., Jeon, M., Lee, J. E., & Nam, S. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6441 · Cited by 46 · see citing works
Interleukin-10
Chang, C., Lam, H. Y. P., Hsu, H., & Jiang, S. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_162_20 · Cited by 46 · see citing works
Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms
Bae, M. S., Han, W., Koo, H. R., Cho, N., Chang, J. M., Yi, A., Park, I., Noh, D., Choi, W. S., & Moon, W. K. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02034.x · Cited by 44 · see citing works
Label-free electrochemical immunosensor based on enhanced signal amplification between Au@Pd and CoFe2O4/graphene nanohybrid
Zhang, Y., Li, J., Wang, Z., Ma, H., Wu, D., Cheng, Q., & Wei, Q. L. (2016) · Scientific Reports · doi:10.1038/srep23391 · Cited by 44 · see citing works
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Lee, J.-M., Hays, J. L., Chiou, V. L., Annunziata, C. M., Swisher, E. M., Harrell, M. I., Yu, M., Gordon, N., Sissung, T. M., Ji, J. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16577 · Cited by 43 · see citing works
Breast Cancer Prevention-Is there a Future for Sulforaphane and Its Analogs?
Kuran, D., Pogorzelska, A., & Wiktorska, K. (2020) · Nutrients · doi:10.3390/nu12061559 · Cited by 43 · see citing works
Targeting Met and Notch in theLfng-deficient,Met-amplified triple-negative breast cancer
Zhang, S., Chung, W.-C., Miele, L., & Xu, K. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28180 · Cited by 43 · see citing works
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis
Spring, K., Fournier, P., Lapointe, L., Chabot, C., Roussy, J., Pommey, S., Stagg, J., & Royal, I. (2015) · Oncogene · doi:10.1038/onc.2015.9 · Cited by 41 · see citing works
Array-based identification of triple-negative breast cancer cells using fluorescent nanodot-graphene oxide complexes
Tao, Y., & Auguste, D. T. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.03.033 · Cited by 41 · see citing works
Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway
Støer, N. C., Vangen, S., Singh, D., Fortner, R. T., Hofvind, S. S. H., Ursin, G., & Botteri, E. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02590-1 · Cited by 40 · see citing works
A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor‐associated macrophages and growth‐arrest specific protein 6
Tian, W., Wang, L., Yuan, L., Duan, W., Zhao, W., Wang, S., & Zhang, Q. (2016) · Cancer Science · doi:10.1111/cas.12964 · Cited by 40 · see citing works
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer
Roig, B., Rodríguez-Balada, M., Samino, S., Lam, E. W. ‐., Guaita‐Esteruelas, S., Gomes, A., Correig, X., Borràs, J., Yanes, Ó., & Gumà, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-17897-8 · Cited by 40 · see citing works
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
He, J., McLaughlin, R. P., van der Noord, V. E., Foekens, J. A., Martens, J. W. M., van Westen, G. J. P., Zhang, Y.-H., & van de Water, B. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05380-z · Cited by 40 · see citing works
Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis
Tsai, Y., Huang, C., Lin, Y., Hsu, C., Huang, C.-P., Liu, C., Chiu, J., & Tseng, L. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02867-x · Cited by 39 · see citing works
Prognostic value of survivin expression in breast cancer patients: a meta-analysis
Song, J., Su, H., Zhou, Y., & Guo, L. (2013) · Tumor Biology · doi:10.1007/s13277-013-0848-2 · Cited by 38 · see citing works
Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
Yi, Y. W., You, K. S., BAE, E. J., Kwak, S., Seong, Y., & Bae, I. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2982 · Cited by 38 · see citing works
The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness
Chandhoke, A. S., Chanda, A., Karve, K., Deng, L., & Bonni, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15471 · Cited by 37 · see citing works
Triple-Negative versus Non–Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study
Podo, F., Santoro, F., Leo, G. D., Manoukian, S., de Giacomi, C., Corcione, S., Cortesi, L., Carbonaro, L. A., Trimboli, R. M., Cilotti, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0459 · Cited by 37 · see citing works
Self-citation
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
Doha, Z. O., Wang, X., Calistri, N. L., Eng, J. R., Daniel, C. J., Ternes, L., Kim, E. N., Pelz, C., Munks, M. W., Betts, C. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40841-6 · Cited by 37 · see citing works

Triple negative breast cancer: Deciphering the biology and heterogeneity
Uscanga‐Perales, G., Santuario-Facio, S. K., & Ortı́z-López, R. (2016) · Medicina Universitaria · doi:10.1016/j.rmu.2016.05.007 · Cited by 45 · see citing works
Explore Genomic Profiles for Triple-Negative Breast Cancer to Discover Drug Targets
Wang, X. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00030-2 · Cited by 2 · see citing works
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Engebraaten, O., Vollan, H. K. M., & Børresen‐Dale, A. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.033 · Cited by 178 · see citing works
Self-citation
Triple Negative Breast Cancer: A Tale of Two Decades
Ali, A., Ansari, J., Abdel-Aziz, N. M., Abozeed, W. N., Warith, A. M. A., Alsaleh, K. A., & Nabholtz, J. (2016) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666160725112335 · Cited by 44 · see citing works
Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment
Li, Y., Kong, X., Wang, Z., & Xuan, L. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17124 · Cited by 32 · see citing works

Authors: Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., Postma, G. J., Schneiderhan-Marra, N., Santoro, F., Wouters, H., Russnes, H. G., Sørlie, T., Tagliabue, E., & Børresen-Dale, A.-L.
Affiliations: Istituto Superiore di Sanità (IT)
Radboud University Nijmegen (NL)
Weizmann Institute of Science (IL)
PamGene (Netherlands) (NL)
Humboldt-Universität zu Berlin (DE)
Norwegian University of Science and Technology (NO)
KU Leuven (BE)
Oslo University Hospital (NO)
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Corresponding author: Podo, Franca
ORCID: Podo, Franca
Hilhorst, Riet
Klipp, Edda
Postma, Geert J.
Russnes, Hege G.
Tagliabue, Elda
Venue: Molecular Oncology
Publisher: Wiley
Published: 2010-04-24
Volume: 4
Issue: 3
Pages: 209-229
ISSN: 1574-7891 (ISSN-L)
1878-0261
DOI: 10.1016/j.molonc.2010.04.006
PMC: PMC5527939
OpenAlex: W2143204308
Cited by: 299
References: 215
Citations by year: 2026: 1 · 2025: 14 · 2024: 10 · 2023: 17 · 2022: 22 · 2021: 16 · 2020: 17 · 2019: 21 · 2018: 33 · 2017: 32 · 2016: 27 · 2015: 24 · 2014: 12 · 2013: 15 · 2012: 15
FWCI: 1.41
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Molecular Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders: Oncology Screening Programme of the Italian Ministry of Health
Italian Association for Cancer Research, AIRC, Milano, Italy
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: triple-negative breast cancer, estrogen receptor, progesterone receptor, HER2, BRCA1 mutation, tumor heterogeneity, gene expression signatures, biomarkers, therapy targets, systems biology, multivariate analysis
MeSH terms: Antineoplastic Agents, Breast Neoplasms, Female, Humans, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Tumor, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, BRCA1 Protein, BRCA2 Protein, Systems Biology, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Triple‐negative breast cancer: Present challenges and new perspectives

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks